Nurix Therapeutics, Inc. 10-Q

Item 5. Other Information (c) Director and Section 16 Officer Rule 10b5-1 Trading Arrangements On February 3, 2026 , Hans van Houte , Chief Financial Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (van Houte Plan), providing for the potential sale of up to 173,860 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Mr. van Houte and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Mr. van Houte. The shares will be sold at the times and prices specified in the van Houte Plan. The van Houte Plan expires on April 30, 2027 , or upon the earlier completion of all authorized transactions thereunder. On February 27, 2026 , Gwenn M. Hansen , Chief Scientific Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (Hansen Plan), providing for the potential sale of up to 52,460 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Dr. Hansen and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Dr. Hansen. The shares will be sold at the times and prices specified in the Hansen Plan. The Hansen Plan expires on May 31, 2027 , or upon the earlier completion of all authorized transactions thereunder. No other director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended February 28, 2026. 93 Table of Contents Item 6. Exhibits Incorporated by Reference Filed or Furnished Herewith Exhibit Number Description Form File No. Exhibit Filing Date 10.1 Amendment No. 3 to the Equity Distribution Agreement, dated March 6, 2026, by and between the Registrant and Piper Sandler & Co. 8-K 001-39398 10.1 March 6, 2026 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1* Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X 101.INS Inline XBRL Instance Document - the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema Document X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X 104 Cover Page Interactive Data File (formatted as Inline XBRL and included in exhibit 101) X * The certifications furnished in Exhibits 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act. 94 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NURIX THERAPEUTICS, INC. Date: April 8, 2026 By: /s/ A RTHUR T. S ANDS Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director (Principal Executive Officer) Date: April 8, 2026 By: /s/ H ANS VAN H OUTE Hans van Houte Chief Financial Officer (Principal Financial and Accounting Officer) 95